文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

AGA 技术评论:成人功能性腹泻和腹泻型肠易激综合征(IBS-D)的评估。

AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D).

机构信息

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada; Department of Oral and Craniofacial Health Science, School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

出版信息

Gastroenterology. 2019 Sep;157(3):859-880. doi: 10.1053/j.gastro.2019.06.014. Epub 2019 Jul 26.


DOI:10.1053/j.gastro.2019.06.014
PMID:31351880
Abstract

BACKGROUND & AIMS: The evaluation of patients with chronic watery diarrhea represents a diagnostic challenge for clinicians because organic causes, including inflammatory bowel disease, microscopic colitis, and chronic infection, must be differentiated from functional diarrhea and diarrhea-predominant irritable bowel syndrome. The purpose of this review is to summarize the available evidence on the usefulness of diagnostic tests in such patients. METHODS: We searched MEDLINE and EMBASE via OVID, from 1978 until April 2017. We included diagnostic test accuracy studies reporting on the use of fecal and blood tests for the evaluation of adult patients with functional diarrhea, including irritable bowel syndrome. We assessed the risk of bias of included studies using a modified version of the Quality Assessment of Diagnostic Accuracy Studies II, and the certainty in the evidence using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. We calculated pooled sensitivity and specificity, and the proportion of patients with true and false positive and negative results. We evaluated the following tests: erythrocyte sedimentation rate, C-reactive protein, fecal lactoferrin, fecal calprotectin, serologic tests for celiac disease, tests for bile acid diarrhea, the commercially available version of anti-cytolethal distending toxin B and anti-vinculin antibodies, and tests for Giardia infection. We did not evaluate breath tests for small intestinal bacterial overgrowth, as they are not part of a standard diarrhea workup. RESULTS: Thirty-eight studies proved eligible to evaluate 1 or more of these tests. Erythrocyte sedimentation rate and C-reactive protein were similar at discriminating organic from functional disease, with sensitivity and specificity, respectively, of 0.54-0.78 and 0.46-0.95 for erythrocyte sedimentation rate and 0.73 and 0.78 for C-reactive protein. Among fecal tests, fecal calprotectin in a range of 50-60 μg/g (pooled sensitivity 0.81; 95% confidence interval [CI], 0.75-0.86; pooled specificity 0.87; 95% CI, 0.78-0.92) and fecal lactoferrin in a range of 4.0-7.25 μg/g (pooled sensitivity 0.79; 95% CI, 0.73-0.84; pooled specificity 0.93; 95%CI 0.63-0.99) presented the lowest proportion of false-negative results (low certainty in the evidence). Among tests for celiac disease, IgA tissue transglutaminase presented the best diagnostic test accuracy (sensitivity range, 0.79-0.99; specificity range, 0.90-0.99) with moderate certainty in the evidence. Among tests for bile acid diarrhea, the selenium homotaurocholic acid test performed better than serum fibroblast growth factor 19 and 7α-hydroxy-4-cholesten-3-one, but is not available in the United States. There was insufficient evidence to recommend serologic tests for irritable bowel syndrome at this time. There are several good diagnostic tests for Giardia infection. CONCLUSIONS: Moderate to low certainty in the evidence indicates that available fecal and blood tests may play a role in the diagnostic workup of adult patients with functional diarrhea. At the moment, no tests are available to reliably rule in irritable bowel syndrome.

摘要

背景与目的:对于临床医生来说,评估慢性水样腹泻患者具有诊断挑战性,因为必须将器质性病因(包括炎症性肠病、显微镜结肠炎和慢性感染)与功能性腹泻和以腹泻为主的肠易激综合征相区分。本文的目的是总结现有关于此类患者诊断性检查有用性的证据。

方法:我们通过 OVID 检索 MEDLINE 和 EMBASE,检索时间截至 2017 年 4 月。我们纳入了报告评估成人功能性腹泻(包括肠易激综合征)患者粪便和血液检查的诊断性检查准确性研究。我们使用改良的诊断准确性研究质量评估工具 II 评估纳入研究的偏倚风险,并使用 GRADE(推荐分级的评估、制定与评价)方法评估证据的确定性。我们计算了汇总的敏感性和特异性,以及真阳性和假阳性及假阴性患者的比例。我们评估了以下检查:红细胞沉降率、C 反应蛋白、粪便乳铁蛋白、粪便钙卫蛋白、针对乳糜泻的血清学检查、胆酸腹泻检查、商用的抗细胞毒素扩张毒素 B 和抗连蛋白抗体检测,以及贾第虫感染检查。我们没有评估小肠细菌过度生长的呼气试验,因为它们不是标准腹泻检查的一部分。

结果:38 项研究被证明有资格评估其中 1 项或多项检查。红细胞沉降率和 C 反应蛋白在区分器质性疾病和功能性疾病方面相似,红细胞沉降率的敏感性和特异性分别为 0.54-0.78 和 0.46-0.95,C 反应蛋白的敏感性和特异性分别为 0.73 和 0.78。在粪便检查中,粪便钙卫蛋白在 50-60μg/g 范围内(汇总敏感性 0.81;95%置信区间 [CI],0.75-0.86;汇总特异性 0.87;95%CI,0.78-0.92)和粪便乳铁蛋白在 4.0-7.25μg/g 范围内(汇总敏感性 0.79;95%CI,0.73-0.84;汇总特异性 0.93;95%CI,0.63-0.99)的假阴性结果比例最低(证据确定性低)。在乳糜泻检查中,IgA 组织转谷氨酰胺酶的诊断性检查准确性最佳(敏感性范围为 0.79-0.99;特异性范围为 0.90-0.99),但证据确定性为中等。在胆酸腹泻检查中,7α-羟基-4-胆甾烯-3-酮比血清成纤维细胞生长因子 19 和硒同型牛磺胆酸检测效果更好,但在美国不可用。目前没有足够的证据推荐使用血清学检查来诊断肠易激综合征。有几种针对贾第虫感染的良好诊断性检查。

结论:证据的确定性为中等至低等,这表明现有的粪便和血液检查可能在成人功能性腹泻的诊断性检查中发挥作用。目前,没有任何检查可以可靠地诊断肠易激综合征。

相似文献

[1]
AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D).

Gastroenterology. 2019-7-26

[2]
AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D).

Gastroenterology. 2019-9

[3]
AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D): Patient Summary.

Gastroenterology. 2019-9

[4]
Spotlight: Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D).

Gastroenterology. 2019-9

[5]
Irritable Bowel Syndrome in Adults (IBS-D): Clinical Decision Support Tool.

Gastroenterology. 2019-9

[6]
ACG Clinical Guideline: Management of Irritable Bowel Syndrome.

Am J Gastroenterol. 2021-1-1

[7]
Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.

Dig Dis Sci. 2017-6

[8]
A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.

Am J Gastroenterol. 2015-3-3

[9]
Evaluation of chronic diarrhea and irritable bowel syndrome with diarrhea in adults in the era of precision medicine.

Am J Gastroenterol. 2018-5-1

[10]
Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis.

Gut. 2015-9-7

引用本文的文献

[1]
2025 Seoul Consensus on Clinical Practice Guidelines for Irritable Bowel Syndrome.

J Neurogastroenterol Motil. 2025-4-30

[2]
Microbiota governs host chenodeoxycholic acid glucuronidation to ameliorate bile acid disorder induced diarrhea.

Microbiome. 2025-2-4

[3]
Management of nonurgent common gastroenterology referrals using primary care clinical pathways: Clinical outcomes, health care use, and avoided costs.

Can Fam Physician. 2024

[4]
Increased Intestinal Inflammation and Permeability in Glaucoma.

J Inflamm Res. 2024-9-30

[5]
[Research status and prospects of probiotics in functional gastrointestinal disorders in infants and toddlers].

Zhongguo Dang Dai Er Ke Za Zhi. 2024-5-15

[6]
Critical appraisal of the SIBO hypothesis and breath testing: A clinical practice update endorsed by the European society of neurogastroenterology and motility (ESNM) and the American neurogastroenterology and motility society (ANMS).

Neurogastroenterol Motil. 2024-6

[7]
Serum Leucine-Rich α2 Glycoprotein Could Be a Useful Biomarker to Differentiate Patients with Normal Colonic Mucosa from Those with Inflammatory Bowel Disease or Other Forms of Colitis.

J Clin Med. 2024-5-17

[8]
Diagnostic Accuracy of Fecal Calprotectin in Discriminating Organic-Inflammatory Gastrointestinal Diseases and Functional Gastrointestinal Disorders in Older Patients.

J Pers Med. 2024-2-21

[9]
Atractylodes macrocephala-Paeonia lactiflora Class Formula for the Treatment of Irritable Bowel Syndrome: A Systematic Review With Meta-Analysis and Trial Sequential Analysis.

Cureus. 2023-12-5

[10]
Methods of Determining Irritable Bowel Syndrome and Efficiency of Probiotics in Treatment: A Review.

Curr Ther Res Clin Exp. 2023-10-18

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索